Reuters logo
BRIEF-Protagonist Therapeutics announces closing of Janssen license
2017年8月24日 / 晚上8点15分 / 1 个月前

BRIEF-Protagonist Therapeutics announces closing of Janssen license

Aug 24 (Reuters) - Protagonist Therapeutics Inc:

* Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment

* Protagonist Therapeutics - ‍following closure of transaction, co received upfront payment of $50 million originally announced by two cos as part of agreement

* Protagonist Therapeutics Inc - ‍PTG-200 is expected to enter phase 1 clinical testing before end of 2017​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below